pharmaphorum Top Stories - 6th January
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
Welcome back to our top stories newsletter, the first of 2025.
In today’s issue, catch up on the news that broke over the holidays, including the first global approval of Daiichi Sankyo’s TROP2-targeting ADC Dato-DXd, and learn more about Regneron’s takeover of UK retinal disease specialist Oxular.
Elsewhere, it’s said that PhRMA could be donating $1m to Trump’s inauguration, and there’s word that London-listed Poolbeg Pharma could be ?merging with Hookipa, while the NHS has disclosed that early cancer diagnoses have risen to record levels in England.
All this and more on pharmaphorum.com.
Top Stories
Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan.
Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.
Trade body PhRMA is among the organisations contributing to what looks like record inaugural fundraising for incoming US President Donald Trump.
领英推è
The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.
Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.
Upcoming webinars
Health Trends 2025: Reimagining What's Possible
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health , entitled ‘Health Trends 2025: Reimagining What's Possible’.
This forward-looking session will explore how imagination and innovation are reshaping the future of healthcare. Our experts will delve into the evolving landscape of life sciences and patient care, driven by cutting-edge technology, data insights, and a renewed commitment to inclusive, patient-centred solutions.